Sentences with phrase «on angiogenesis»

I am not sure about overdosing on angiogenesis inhibitors.

One of the early pioneers of angiogenesis research, Dr. Konerding leads a group focusing on angiogenesis in inflammation, wound healing, and tumor growth, as well as on clinical anatomy.

In 2001, she co-organized Columbia University's first Arden House symposium on angiogenesis.

Thalidomide's penchant for targeting blood vessels in tumors made Mummery wonder whether the drug's effect on angiogenesis could help HHT sufferers.

The study examined the effects of salivary peptide histatin - 1 on angiogenesis (blood vessel formation), which is critical to the efficiency of wound healing.

Not exact matches

«Nintedanib [a drug that there is more experimental data on] is an improved antiangiogenic drug compared to previous angiogenesis inhibitors, given that it prevents angiogenesis in a more efficient way and with lower toxicity than its predecessors,» explains Quintela.

Nintedanib, in addition to blocking vascular endothelial growth factor receptors (VEGFR) and platelet derived growth factor receptors (PDGFR), also acts on fibroblast growth factor receptors (FGFR), which makes it different to classical angiogenesis inhibitors.

In the presence of these drugs tumors grow faster and develop more extensive networks of the blood vessels they rely on to feed their expansion — a process called angiogenesis, says Jonathan Moss, an anesthesiologist at the University of Chicago (U. of C.) Medical Center.

He then carried out his doctoral research on cancer angiogenesis at the University of Nottingham, followed by an appointment in the Laboratory for Experimental Cartilage Research, initially as postdoc and then as a group head.

«Our study provides the first evidence that endothelial CD146 plays a dual role on endothelium, facilitating leukocyte extravasations and angiogenesis, thus promoting inflammation,» says Dr. Yan.

They focused towards this end on the vascular growth factor Angiopoietin - 2, which is produced by endothelial cells and does not just control angiogenesis, but acts as a key responsiveness factor for endothelial cells.

They are driven by stem cells with the proneural pattern of gene expression and depend on rapid cell division and angiogenesis — creation of new blood vessels.

It is now firmly established that the growth and metastasis of the vast majority of neoplasms are dependent on the formation of adequate vasculature, i.e., angiogenesis (1, 2, 3).

The formation of new blood vessels from existing vessels, known as angiogenesis, depends on a sequential process that involves endothelial cells (EC) and pericytes1.

If anything, the incomplete recombination of Tie2 in pericytes would have underestimated the effect of Tie2 deletion on tumour angiogenesis.

His research interests focus on understanding basic underlying mechanisms of ocular angiogenesis and identifying therapeutic approaches to treating neovascular eye diseases such as macular degeneration and diabetic retinopathy.

As an active researcher, much of her work is focused on regulation of angiogenesis in pediatric solid tumors, including Wilms» tumor, neuroblastoma, and hepatoblastoma.

Furthermore, we will expand on studies related to the regulation of vascular homeostasis, as well as related to the regulation of inflammation by angiogenesis.

He is an expert on microvascular anatomy and patterns of angiogenesis and the effects of antiangiogenic agents in blood vessels in different organ and tissue systems.

Dr. Richard Beliveau is Director of the Laboratory of Molecular Medicine at Service de Neurochirurgie, Hopital, Notre - Dame (CHUM), and an expert on tumor angiogenesis.

Dr. Harris is a renowned expert on the role of COX - 2 in chronic inflammation and in promoting tumorigenesis and angiogenesis, and has authored numerous papers in peer - reviewed journals and book chapters on the use of NSAIDS and selective COX - 2 inhibitors in the chemoprevention of various cancer types.

On the other hand, the present research work shows a confirmatory evidence of the potential of kahweol to inhibit in vivo angiogenesis, by using another completely independent model system, namely, that of genetically modified zebrafish.

Mesenchymal stem cells (MSCs) promote angiogenesis in ischemic diseases and have neuroprotective effects, particularly on Schwann cells.

We really wanted to find a compound, a chemical, that would profoundly stop the growth of blood vessel cells, which of course are the cells that go on to form the abnormal angiogenesis in wet AMD.

The CAM and zebrafish in vivo assays and the ex vivo mouse aortic ring assay clearly identify kahweol as a new anti-angiogenic compound, but gives no information on which specific steps of angiogenesis are targeted by this compound.

However, the exact cytoskeletal strategy that the cell uses to cross the physical BM barrier depends on the physiological context and the physical environment, as observed by examining actin structures in invading cancer and immune cells, and in cells that invade during developmental processes such as angiogenesis and anchor cell invasion in Caenorhabditis elegans.

To characterize an anti-angiogenic compound, it is advisable to study its effects on the different steps involved in angiogenesis.

We show for the first time that kahweol is an anti-angiogenic compound with inhibitory effects in two in vivo and one ex vivo angiogenesis models, with effects on specific steps of the angiogenic process: endothelial cell proliferation, migration, invasion and tube formation on Matrigel.

Our objective is to determine whether this mutation is involved in AMD by (1) understanding the functional consequences of this genomic variation on expression of COL8A1 and / or its neighbor genes, and (2) investigating photoreceptors and RPE cell survival, retinal and choroidal angiogenesis, structure integrity of the choroid / Bruch's membrane, and the quality of the vision, in organisms with the COL8A1 mutation.

The data presented in this article suggests that tumor subtype needs to be taken into account during treatment design as blocking angiogenesis and therefore increasing tumor hypoxia may be beneficial in the treatment of ER - α — negative breast cancer but could have catastrophic effects on ER - α — positive breast cancer.

I am a motivated medical writer with over 12 years of research experience in multiple labs, working on a variety of biochemical topics, centering on the role of kinases in hypertension, angiogenesis and tumor development.

NOTE: Bovine tracheal cartilage (BTC) can be found on the market by various names: Antitumor angiogenesis factor, bovine mucopolysaccharide - cartilage complex, Catrix ®, Catrix ® - S, collagen bovine, cow cartilage, glycosaminoglycan polysulfuric acid complex, metastatin, mucopolysaccharide - cartilage complex, processed bovine cartilage, psoriacin, psoriacin - T, Rumalon ®, VitaCarte ®, Dr Rons and Vital Proteins.

Mushrooms have quite an array of beneficial properties: Studies on different types of mushrooms have found anti-inflammatory effects, enhanced immune cell activity, prevention of DNA damage, slowed cancer cell growth, and angiogenesis inhibition.

Also, a 2012 study published on the Medical Journal 3 Biotech shows that the anti-cancer compounds in mushrooms play a crucial role as a reactive oxygen species inducer, mitotic kinase inhibitor, antimitotic, angiogenesis inhibitor, topoisomerase inhibitor all leading to apoptosis (cell death) and eventually checking cancer cell proliferation (4).

DIM was found to alter angiogenesis, the lay - down of new vessels that cancers rely on for continued growth.

The multiplication of cancer cells depends on an adequate supply of oxygen, and in order to obtain this supply of oxygen, cancer cell growth is often accompanied by the formation of new blood vessels (through a process called angiogenesis).

Dr Li of the Angiogenesis Foundation gave a TED talk on this in 2010.

Well, we need to know the relative importance of the three ingredients on the left side of the above equation in producing angiogenesis.